Chemoimmunotherapy Linked to HNSCC Response - Summary - MDSpire

Chemoimmunotherapy Linked to HNSCC Response

Higher pathologic response rates with chemoimmunotherapy versus immunotherapy alone call for phase 3 trials, but survival implications remain unknown.

  • By

  • Andrea Surnit

  • June 5, 2026

  • 6 min

Share

Objective:

To evaluate the efficacy of neoadjuvant chemoimmunotherapy compared to neoadjuvant immunotherapy alone in patients with resectable head and neck squamous cell carcinoma (HNSCC).

Key Findings:
  • Pooled MPR plus CPR rates were 66% for chemoimmunotherapy, 18% for dual-agent immunotherapy, and 6% for single-agent immunotherapy.
  • CPR rates were 38%, 5%, and approximately 3% for the respective treatment groups.
  • Radiographic response rates favored chemoimmunotherapy with 66% showing partial or complete responses compared to 9% and 6% for dual-agent and single-agent immunotherapy, respectively.
  • Adverse events (grade 3 to 5) occurred in 17% of patients receiving chemoimmunotherapy, 3% for dual-agent, and 29% for single-agent immunotherapy.
Interpretation:

Limitations:
  • Many included trials were single-group studies, limiting direct comparisons.
  • High heterogeneity across chemoimmunotherapy trials.
  • Subgroup analyses by disease subsite, stage, or HPV status could not be performed.
  • Inconsistent reporting of survival outcomes and adverse events.
Conclusion:

Original Source(s)

Chemoimmunotherapy Linked to HNSCC Response

  • by Andrea Surnit

  • June 5, 2026

Related Content

The Bill Nobody's Discussing in the Exam Room

Head and neck cancer costs are crushing patients — yet cost discussions remain uncommon in clinical care.

FDA Grants Accelerated Approval for OTOF Gene Therapy

A one-time intracochlear gene therapy improved hearing outcomes in patients with OTOF-related sensorineural hearing loss in the phase 1/2 CHORD trial.

Side Effects: Turns Out, Never Mind

Red meat didn't wreck the pancreas. Sauna doesn't do what we thought. Loneliness doesn't accelerate decline. A week of quietly overturned assumptions.